// App-Quantinova.ai

EP38 : Secukinumab provides sustained improvement of enthesitis in patients with ankylosing spondylitis: pooled analysis of four pivotal Phase 3 studies

Researchers

Presenter

  • Nick Barkham

Principal Investigators

  • Georg Schett

  • Xenofon Baraliakos

  • Filip van den Bosch

  • Atul Deodhar

  • Lianne S Gensler

  • Mikkel ?stergaard

  • Shital Agawane

  • Ayan Das Gupta

  • Shephard Mpofu

  • Todd Fox

  • Adam Winseck

  • Abhijit Shete

  • Brian Porter

Medical Centers

  • Rheumatology, New Cross Hospital, Wolverhampton, UNITED KINGDOM

  • Department of Internal Medicine , Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany

  • Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany

  • Department of Rheumatology, Ghent University Hospital, Ghent, BELGIUM

  • Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR

  • Ankylosing Spondylitis Clinic, University of California, San Francisco, CA, USA

  • Copenhagen Center for Arthritis Research, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark

  • Novartis Healthcare Pvt Ltd, Hyderabad, Telangana, INDIA

  • Immunology, Hepatology, and Dermatology Development Unit, Novartis Pharma AG, Basel, SWITZERLAND

  • Immunology, Dermatology and Rheumatology/Autoimmunity, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Locations

  • United Kingdom

  • Germany

  • Belgium

  • United States

  • Denmark

  • India

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Ankylosing spondylitis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved